Microsoft word - eyegatepr_jan2011_final.doc
FOR IMMEDIATE RELEASE:
EyeGate Pharma Secures Additional $5.9M Series D Venture Funding
Waltham, MA – January 5, 2011 –
EyeGate Pharma, a privately held venture-backed
pharmaceutical company developing ocular therapeutics, announces today that it has secured an
additional $5.9M as part of its Series D closing. With this additional tranche, Eyegate has
raised a total of $28.5M in Series D funding to date.
The funds will be used to continue development of EGP-437 for the treatment of Dry Eye
Syndrome (DES), an ocular surface irritation affecting several million men and women in the
United States. EGP-437 is a dexamethasone derived corticosteroid solution specially
formulated for delivery using the EyeGate® II Delivery System. EGP-437 is part of EyeGate’s
broader strategy of developing a pipeline of medicines for treating ocular diseases using its
proprietary EyeGate® II Delivery System, a non-invasive, iontophoretic drug delivery system.
Currently, the ALLUVION Phase III study of EGP-437 in patients with DES is fully enrolled,
awaiting last patient last visit, and top-line data, which is expected by the end of the first
quarter 2011. A prior Phase II study demonstrated significant improvements in the signs and
symptoms of dry eye during and after Controlled Adverse Experiment (CAE) exposure.
EyeGate is the first company to complete Phase II studies using iontophoresis technology to
deliver an active compound into the eye under an investigational new drug (IND) application.
At 2:30 pm on Tuesday, January 11, 2011, Stephen From, President and CEO of EyeGate
Pharma, will speak at the Biotech ShowcaseTM 2011, which is being held in San Francisco. The
Biotech ShowcaseTM provides life science companies the opportunity to present to an audience
of investors and business development executives.
About Iontophoresis as a Drug Delivery Approach
The EyeGate® II Delivery System works through the process of iontophoresis: an active
method of drug delivery in which an electrical field created by a low-level of electrical current
is used to ionize a drug and to modify the permeability of the cells so that the drug can be
delivered through different tissues to the target areas. These principles can be applied to both
anionic and cationic molecules. To deliver a therapeutic to both the anterior (front) and
posterior (back) tissues of the eye, the drug must be specifically adapted and formulated for
iontophoretic delivery. EyeGate has concentrated its efforts on optimizing the EyeGate® II
Delivery System to administer a wide range of therapeutics and developing a highly specialized
laboratory dedicated to formulating drugs for iontophoretic delivery.
About EyeGate Pharma
Eyegate Pharmaceuticals, Inc. is focused on developing treatments for unmet ocular medical
needs by employing the EyeGate® II Ocular Drug Delivery System, a non-invasive drug delivery
technology. The EyeGate® II delivery system is compatible with a wide range of therapeutics;
therefore, it has the potential to address many anterior and posterior segment diseases. EyeGate
Pharma is the first company to demonstrate clinical significance utilizing iontophoresis and the
EyeGate® II delivery system has been studied in over 350 subjects (over 1,200 treatments
performed). The Company has completed randomized, double-masked Phase II clinical studies in
both dry eye and uveitis studying its lead product candidate (EGP-437), and awaits results of a
Phase III study (ALLUVION) in dry eye patients. EyeGate has ongoing relationships with other
biotech and pharmaceutical companies (e.g., RXi). For more information, please visit
Contact:Stephen FromPresident & CEOsdfrom@eyegatepharma.com781-398-3820
Protokoll Der 111. ordentlichen Generalversammlung des Schweizerischen Collie-Clubs Samstag, 02. März 2013, 09.30 Uhr im Hotel Weisses Kreuz, Marktplatz 15, 3250 Lyss 1. Vortraktanden Die Präsidentin Rosmarie Abbühl begrüsst die Mitglieder und Gäste zur 111.Generalversammlung und heisst sie al e herzlich wil kommen. Namentlich werden begrüsst: Peter Reichenbach, Ehrenmitglied
Vatikanoko II. Kontzilioaz haratago gaurko kulturatik bi arotara, bi eoitara. are bizkorrago eta kementsuago jarrai -tzen du aurrera. 1. Mundu modernoarekin adiski- detu raino bakarrik iritsi zela. Eta erdibide-listaren artean, mundua tragikoki bana-tua zegoela, herrialde kolonizatuenzuen, eta erdizka bakarrik lortu; bitar-tean, ordea –Kontzilioko eta ondoren-go urteetan– kultu